Join our daily newsletter At The Bell to receive exclusive market insights
Regenerative medicine company Orthocell (ASX:OCC) has published encouraging findings from its Remplir nerve regeneration clinical trial, unveiling promising progress in its peripheral nerve repair journey – offering hope for millions of people.
The Remplir study, published in the peer-reviewed Journal of Reconstructive Microsurgery Open showed advances in the restoration of muscle functions to people using RemplirTM. who were suffering paralysis of the upper limbs
These results indicated that 85% of nerve repairs with Remplir showed functional recovery of 24 months post-treatment.
Orthocell’s Remplir is an effective medical device for connecting severed nerves, protecting damaged nerves, or capping amputated nerves.
Orthocell aims to establish Remplir as a leading device in the USA, targeting an estimated market value of US$1.1 billion annually.
Orthocell anticipates top-line results from its US FDA Remplir nerve repair study due in the third quarter of CY24. The company remains on track to submit its US 510(K) market authorization application in the fourth quarter of CY24, and plans to commercialise the device shortly thereafter.
These findings mark a step up in peripheral nerve repair outcomes and provides hope to patients suffering from upper limb paralysis and damaged nerves.
OCC has been trading at 39 cents.
